Claims
- 1. A method for inhibiting aldose reductase comprising: employing a chromone derivative or a pharmaceutically acceptable salt thereof represented by Formula (I): ##STR9## wherein R.sub.1 and R.sub.2 are selected from the group consisting of a hydrogen atom, a lower alkyl group, a lower alkenyl group, an aliphatic acyl group and an aromatic acyl group; R.sub.3 represents a sulfur atom; R.sub.4 is selected from the group consisting of a hydrogen atom and a lower alkoxy group; R.sub.7 is selected from the group consisting of a phenyl, benzyl, and a nitrogen-containing heterocyclic group selected from the group consisting of pyridyl, benzimidazolyl, benzthiazolyl, thiazolynyl and thiadiazolyl, substituted or unsubstituted, wherein substituents are selected from the group consisting of C.sub.1-6 alkyl group, a halogen atom, an amino, hydroxy, nitro, carboxyl, hydroxymethyl, methylenedioxy, C.sub.1-6 alkoxy, C.sub.2-6 alkenyloxy, C.sub.1-6 alkoxycarbonyl, tert-butyldimethylsilyloxy, a glycyloxy group, a .beta.-aspartyloxy group, a 4-(4-methylpiperazinomethyl)benzoyloxy group and a benzoyloxy group.
- 2. A method according to claim 1, wherein R.sub.7 is a substituted phenyl group wherein substituents are selected from the group consisting of C.sub.1-6 alkyl group, a halogen atom, an amino, hydroxy, nitro, carboxyl, hydroxymethyl, methylenedioxy, C.sub.1-6 alkoxy, C.sub.2-6 alkenyloxy, C.sub.1-6 alkoxycarbonyl, tert-butyldimethylsilyloxy, a glycyloxy group, a .beta.-aspartyloxy group, a 4-(4-methylpiperazinomethyl)benzoyloxy group and a benzoyloxy group.
- 3. A method according to claim 1, wherein R.sub.1 is selected from the group consisting of ethyl and a branched alkyl group represented by Formula (II): ##STR10## wherein R.sub.8 and R.sub.9 are each selected from the group consisting of methyl and ethyl; and R.sub.2 is selected from the group consisting of a hydrogen atom, methyl, ethyl and a branched alkyl group represented by Formula (II).
- 4. A method according to claim 1, wherein R.sub.1 is selected from the group consisting of ethyl and a branched alkyl group represented by Formula (II): ##STR11## wherein R.sub.8 and R.sub.9 are each selected from the group consisting of methyl and ethyl; and R.sub.2 is selected from the group consisting of a hydrogen atom, methyl, ethyl and a branched alkyl group represented by Formula (II) and R.sub.7 represents a phenyl group substituted by a hydroxy group.
- 5. A method for inhibiting aldose reductase according to claim 1 comprising employing a chromone derivative or a pharmaceutically acceptable salt thereof selected from the group consisting of 5,7-diisopropoxy-2-(4-hydroxyphenylthio)-6-methoxychromone, 5,7-diethoxy-2-(4-hydroxyphenylthio)-6-methoxychromone, 5,7-di-s-butoxy-2-(4-hydroxyphenylthio)-6-methoxychromone, 7-s-butoxy-2-(4-hydroxyphenylthio)-5-isopropoxy-6-methoxychromone, 5-ethoxy-2-(4-hydroxyphenylthio)-7-isopropoxy-6-methoxychromone, 5-hydroxy-2-(4-hydroxyphenylthio)-7-isopropoxy-6-methoxychromone, 5,6-dimethoxy-2-(4-hydroxyphenylthio)-7-isopropoxychromone, 7-s-butoxy-5,6-dimethoxy-2-(4-hydroxyphenylthio)chromone, 5,6-dimethoxy-7-(1-ethylpropoxy)-2-(4-hydroxyphenylthio)chromone and 5,7-diisopropoxy-2-(4-hydroxyphenylthio)chromone.
- 6. A method according to claim 1, wherein the chromone derivative or pharmaceutically acceptable salt thereof is employed by administering the chromone derivative or pharmaceutically acceptable salt to a patient with diabetes.
- 7. A method according to claim 6, comprising the further step of treating a symptom of diabetes.
- 8. A method for inhibiting aldose reductase comprising: employing a chromone derivative or a pharmaceutically acceptable salt thereof represented by Formula (I): ##STR12## wherein R.sub.1 and R.sub.2 are selected from the group consisting of a hydrogen atom, a lower alkyl group, a lower alkenyl group, and an acyl group; R.sub.3 represents a sulfur atom; R.sub.4 is selected from the group consisting of a hydrogen atom and a lower alkoxy group; R.sub.7 represents a phenyl group which is substituted by a hydroxy group, a glycyloxy group, .beta.-aspartyloxy or a 4-(4-methylpiperazinomethyl)benzoyloxy group.
- 9. A method according to claim 8, wherein R.sub.1 is selected from the group consisting of ethyl and a branched alkyl group represented by Formula (II): ##STR13## wherein R.sub.8 and R.sub.9 are each selected from the group consisting of methyl and ethyl; and R.sub.2 is selected from the group consisting of a hydrogen atom, methyl, ethyl and a branched alkyl group represented by Formula (II).
- 10. A method for inhibiting aldose reductase according to claim 8 comprising: employing a pharmaceutically acceptable acid addition salt of compound of Formula (I) wherein R.sub.7 represents a phenyl group which is substituted by a glycyloxy group, .beta.-aspartyloxy, or a 4-(4-methylpiperazinomethyl)benzoyloxy group.
- 11. A method according to claim 8, wherein the chromone derivative or pharmaceutically acceptable salt thereof is employed by administering the chromone derivative or pharmaceutically acceptable salt to a patient with diabetes.
- 12. A method according to claim 11, comprising the further step of treating a symptom of diabetes.
- 13. A method for inhibiting aldose reductase according to claim 1 comprising employing a chromone derivative or a pharmaceutically acceptable acid addition salt of a compound of Formula (I) wherein R.sub.7 represents a phenyl group which is substituted by a glycyloxy group, a .beta.-aspartyloxy group or a 4-(4-methylpiperazinomethyl)benzoyloxy group.
- 14. A method for inhibiting aldose reductase according to claim 1 comprising employing a chromone derivative or a pharmaceutically acceptable salt thereof selected from the group consisting of 5,6-dimethoxy-2-(4-glycyloxyphenylthio)-7-isopropoxychromone hydrochloride, 5-ethoxy-2-(4-glycyloxyphenylthio)-7-isopropoxy-6-methoxychromone hydrochloride, 7-(1-ethylpropoxy)-5,6-dimethoxy-2-(4-glycyloxyphenylthio)chromone hydrochloride, 2-(4-.beta.-aspartyloxyphenylthio)-5-ethoxy-7-isopropoxy-6-methoxychromone hydrochloride, 5,6-dimethoxy-7-(1-ethylpropoxy)-2-{4-[4-(4-methylpiperazinomethyl)benzoyloxy]phenylthio}chromone dihydrochloride and 7-(1-ethylpropoxy)-5-hydroxy-2-{4-[4-(4-methylpiperazinomethyl)benzoyloxy]phenylthio}-6-methoxychromone dihydrochloride.
- 15. A method according to claim 6, comprising the further step of preventing a symptom of diabetes.
- 16. A method according to claim 11, comprising the further step of preventing a symptom of diabetes.
Priority Claims (2)
Number |
Date |
Country |
Kind |
2-330519 |
Nov 1990 |
JPX |
|
2-330520 |
Nov 1990 |
JPX |
|
Parent Case Info
This is a divisional of application Ser. No. 08/322,396, filed Oct. 12, 1994, now U.S. Pat. No. 5,455,267, which was a file wrapper continuation of application Ser. No. 07/915,995 filed Jul. 30, 1992, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4532254 |
Okuda et al. |
Jul 1985 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
54-114768 |
Sep 1979 |
JPX |
58-99414 |
Jun 1983 |
JPX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
322396 |
Oct 1994 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
915995 |
Jul 1992 |
|